A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Latest Information Update: 10 Mar 2022
At a glance
- Drugs Neladenoson bialanate (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms PANTHEON
- Sponsors Bayer
- 16 Sep 2019 Primary endpoint has not been met. (Absolute change from baseline in log-transformed NT-proBNP (N-terminal pro-hormone b-type natriuretic peptide ) (pg/mL) after 20 weeks)
- 16 Sep 2019 Primary endpoint has not been met. (Absolute change from baseline in left ventricular ejection fraction (LVEF; %) after 20 weeks)
- 16 Sep 2019 Results published in the European Journal of Heart Failure